Compare PEB & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEB | PHVS |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 2009 | 2020 |
| Metric | PEB | PHVS |
|---|---|---|
| Price | $18.35 | $37.23 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 11 |
| Target Price | $13.30 | ★ $41.82 |
| AVG Volume (30 Days) | ★ 2.0M | 558.5K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,475,544,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.25 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.53 | N/A |
| 52 Week Low | $9.99 | $20.65 |
| 52 Week High | $19.93 | $38.13 |
| Indicator | PEB | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 48.62 | 63.27 |
| Support Level | $18.35 | $24.73 |
| Resistance Level | $19.73 | N/A |
| Average True Range (ATR) | 0.51 | 1.78 |
| MACD | -0.01 | 0.26 |
| Stochastic Oscillator | 57.28 | 88.50 |
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,052 rooms across 44 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.